This transcript has been edited for clarity.
Ileana Piña, MD, MPH: Hello. I'm Ileana Piña from Central Michigan University, and this is my blog. We are reporting on the American College of Cardiology national meeting which, once again this year, is virtual. The late-breaking sessions have been fabulous and I've been watching most of them from early in the morning. One that was presented on Sunday morning was from my good friend, Dalane Kitzman, who is professor of medicine and the Phillips Chair of Cardiovascular Medicine at Wake Forest School of Medicine. For all the time I've known Dalane, he has been consumed with heart failure with preserved ejection fraction (HFpEF). I think he knows more about the syndrome than anyone else in the country.
His other love is geriatric cardiology. Today he presented results of REHAB-HF, a fascinating study for those of us who are involved with cardiac rehab.
Welcome, Dalane. Thank you for taking the time to join us. First, give us an overview of the trial. What were you trying to accomplish, and what did you accomplish?
Dalane Kitzman, MD: Thank you, Ileana. I'm honored to be here. REHAB-HFgrew out of the observation that older persons hospitalized for acute decompensated heart failure have very poor outcomes, frequent rehospitalizations, poor quality of life, and high death rates, and a range of interventions aimed at improving their outcomes have been neutral.
COMMENTARY
REHAB-HF Lays the Groundwork for Recovery of Function After Acute HF
Ileana L. Piña, MD, MPH; Dalane Kitzman, MD
DisclosuresMay 24, 2021
This transcript has been edited for clarity.
Ileana Piña, MD, MPH: Hello. I'm Ileana Piña from Central Michigan University, and this is my blog. We are reporting on the American College of Cardiology national meeting which, once again this year, is virtual. The late-breaking sessions have been fabulous and I've been watching most of them from early in the morning. One that was presented on Sunday morning was from my good friend, Dalane Kitzman, who is professor of medicine and the Phillips Chair of Cardiovascular Medicine at Wake Forest School of Medicine. For all the time I've known Dalane, he has been consumed with heart failure with preserved ejection fraction (HFpEF). I think he knows more about the syndrome than anyone else in the country.
His other love is geriatric cardiology. Today he presented results of REHAB-HF, a fascinating study for those of us who are involved with cardiac rehab.
Welcome, Dalane. Thank you for taking the time to join us. First, give us an overview of the trial. What were you trying to accomplish, and what did you accomplish?
Dalane Kitzman, MD: Thank you, Ileana. I'm honored to be here. REHAB-HFgrew out of the observation that older persons hospitalized for acute decompensated heart failure have very poor outcomes, frequent rehospitalizations, poor quality of life, and high death rates, and a range of interventions aimed at improving their outcomes have been neutral.
© 2021 WebMD, LLC
Any views expressed above are the author's own and do not necessarily reflect the views of WebMD or Medscape.
Cite this: Ileana L. Piña, Dalane Kitzman. REHAB-HF Lays the Groundwork for Recovery of Function After Acute HF - Medscape - May 24, 2021.
Tables
Authors and Disclosures
Authors and Disclosures
Author(s)
Ileana L. Piña, MD, MPH
Professor of Medicine, Wayne State University; Clinical Professor of Medicine, Central Michigan University; Director of CVD Research and Academic Affairs; Regional and National Director of Heart Failure, Detroit Medical Center, Detroit, Michigan
Disclosure: Ileana L. Piña, MD, MPH, has disclosed the following relevant financial relationships:
Serve(d) as a director, office, partner, employee, advisor, consultant, or trustee for: US Food and Drug Administration; Center for Devices and Radiological Health
Dalane Kitzman, MD
Professor, Department of Medicine, Wake Forest School of Medicine, Winston-Salem, North Carolina
Disclosure: Dalane Kitzman, MD, has disclosed the following relevant financial relationships:
Serve(d) as a director, officer, partner, employee, advisor, consultant, or trustee for: AstraZeneca; DCRI; Boehringer Ingelheim; Merck; Pfizer; Novartis; Corvia; Bayer; NovoNordisk
Received research grant from: Novartis; AstraZeneca; Pfizer; St. Luke's; Bayer; NovoNordisk
Received income in an amount equal to or greater than $250 from: AstraZeneca; DCRI; Boehringer Ingelheim; Merck; Pfizer; Novartis; Corvia; Bayer; NovoNordisk